NASDAQ : VALN
Valneva SE — Key statistics
Healthcare · Biotechnology · France
Last price 5.71 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 541.61M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 519.43M |
| Enterprise Value | 618.48M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | n/a |
| Shares Outstanding | 189.65M |
| Shares Change (YoY) | +13.10% |
| Shares Change (QoQ) | +2.92% |
| Owned by Insiders (%) | 1.31% |
| Owned by Institutions (%) | 25.13% |
| Float | 171.36M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | 181.67 |
| PS Ratio | 3.18 |
| Forward PS | 2.90 |
| PB Ratio | 5.60 |
| P/TBV Ratio | 7.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 3.79 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 2.16 |
| Quick Ratio | 1.33 |
| Debt / Equity | 2.59 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.83 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -117.85% |
| Return on Assets (ROA) | -16.68% |
| Return on Invested Capital (ROIC) | -65.51% |
| Return on Capital Employed (ROCE) | -40.32% |
| Weighted Average Cost of Capital (WACC) | 12.46% |
| Revenue Per Employee | $263,390 |
| Profits Per Employee | -$290,499 |
| Employee Count | 620 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 3.69 |
Taxes
| Measure | Value |
|---|
| Income Tax | 91,397 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.26 |
| 52-Week Price Change | -40.24% |
| 50-Day Moving Average | 6.18 |
| 200-Day Moving Average | 6.82 |
| Relative Strength Index (RSI) | 42.12 |
| Average Volume (20 Days) | 23,039 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 191,916 |
| Short Previous Month | 206,846 |
| Short % of Shares Out | 0.21% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 8.16 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 163.30M |
| Gross Profit | -68.15M |
| Operating Income | -131.27M |
| Pretax Income | -180.02M |
| Net Income | -180.11M |
| EBITDA | -112.79M |
| EBIT | -131.27M |
| Loss Per Share | -$1.98 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 138.84M |
| Total Debt | 240.18M |
| Net Cash | -101.34M |
| Net Cash Per Share | -$0.53 |
| Equity (Book Value) | 92.68M |
| Book Value Per Share | 0.49 |
| Working Capital | 136.58M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -62.50M |
| Capital Expenditures | -2.63M |
| Depreciation & Amortization | 18.15M |
| Net Borrowing | -484,814 |
| Free Cash Flow | -65.13M |
| FCF Per Share | -$0.34 |
Margins
| Measure | Value |
|---|
| Gross Margin | -41.73% |
| Operating Margin | -80.38% |
| Pretax Margin | -110.24% |
| Profit Margin | -110.29% |
| EBITDA Margin | -69.07% |
| EBIT Margin | -80.38% |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -13.10% |
| Shareholder Yield | -13.10% |
| Earnings Yield | -36.37% |
| FCF Yield | -12.54% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $12.28 |
| Price Target Difference | 125.32% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (3Y) | 12.44% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -1.73 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |